Home Page  Journal Archive  Members
 Instructions to Authors  Send Article  Join Us
 Contact Us  Site Map
Username
Password
Membership Request
Forget Password
CHAIRMAN MANAGER
Vahidi Serajedin M.D.

EDITOR- IN- CHIEF
Aflatoonian Abbas M.D.

MANAGING EDITOR
Anvari Morteza Ph.D.

EXCUTIVE BOARD
Abdoli Ali Mohammad M.D.
Asadzadeh Kobra B.S.
Khani Parisa M.D.
Mortazavifar Zahrasadat B.S.
Sheikhha Mohammad Hasan M.D. Ph.D.
 
Home Page :: Journal members panel

Journal Title: Autumn 2009
Article title: Developmental consequences of mouse cryotop-vitrified oocyte and embryo using low concentrated cryoprotectants

Article PDF File:
Page From: 181 To: 188      

Article abstract:
Background: The risk of multiple pregnancies often present in programs of In Vitro Fertilization (IVF) is an important force for embryo cryopreservation. On the other hand ethical restriction and assurance of potential fertility following chemo/radio therapy has led scientists to focus on female gamete preservation. Objective: Optimizing vitrification protocol by using less concentrated cryoprotectants (CPAs) in order to decrease CPAs toxicity. Materials and Methods: Mouse Metaphase-II (M-II) oocytes and four cell-stage embryos were collected. Oocytes Survival Fertilization and Developmental Rates (SRs FRs DRs) were recorded after cryotop-vitrification/warming. As well as comparing fresh oocytes and embryos the data obtained from experimental groups (exp.) applying 1.25 1.0 0.75 molar (M) CPAs were analyzed in comparison to those of adopting 1.5 M CPAs [largely-used concentration of Ethylen Glycol (EG) and Dimethyl-sulphoxide (DMSO)]. Results: The data of oocytes exposed to 1.25 M concentrated CPAs were in consistency with those exposed to 1.5 M and control group in terms of SR FR and DR. As less concentration was applied the more decreased SRs FRs and DRs were obtained from other experimental groups. The results of embryos which were exposed to 1.25 M and 1.0 M were close to those vitrified with 1.5 M and fresh embryos. The results of 0.75 M concentrated CPAs solutions were significantly lower than those of control 1.5 M and 1.0 M treated groups. Conclusion: CPAs limited reduction to 1.25 M and 1.0 M instead of using 1.5 M for oocyte and embryo cryotop-vitrification procedure may be a slight adjustment.

Article KeyWords:
Cryotop Cryoprotectant Embryo Mouse Oocyte Vitrification.

Article Authors:
Sahar Almasi-TurkFirst Author
Amrollah RoozbehiOther Author
Elham ElhamOther Author
Ali HaeriOther Author
Yoosef Other Author
Ahmad HosseiniCorresponding Author




Home Page  |   Contact Us  |   Send Article  |   Site Map  

استفاده از مطالب این سایت با ذکر نام سایت مجاز می باشد   -   Copyright © 2007 2009 - Last Update 5-11-2009
Powered By www.itpco.net    www.itpco.ir
( ITPCO ) شرکت توسعه انفورماتیک ایران
تولید کننده سیستم های تخصصی مدیریت نشریات و همایش ها و مورد تائید کمیسیون نظارت بر نشریات پزشکی وزارت بهداشت درمان و آموزش پزشکی کشور